Home
This site is intended for healthcare professionals

PMG Academy | Advancing Clinical Expertise: Applying Emerging Therapeutic Advances

Share

Description

This activity is supported by an independent education grant from ArgenX. This online education program has been designed for healthcare professionals in the United States.

Targeted therapies are expanding the treatment landscape for Pediatric Myasthenia Gravis (PMG), offering mechanism-specific disease control while reducing the cumulative burden of broad immunosuppression. Led by Dr. Abigail N. Schwaede, this session evaluates the current pediatric evidence base, regulatory approvals, and practical protocols for integrating complement inhibitors and FcRn blockers into clinical practice.

Session Highlights

  • Mechanisms & Antibody-Driven Selection: Match targeted therapies to antibody status, understanding why complement inhibition is restricted to AChR-positive disease, while FcRn blockade and B-cell depletion provide mechanistically rational options for MuSK-positive patients.
  • Pediatric Labelling & Evidence Gaps: Review the US pediatric indications for eculizumab and nipocalimab, noting that current pediatric approvals are grounded in adult efficacy and pediatric safety/pharmacokinetic data rather than randomized pediatric clinical trials.
  • Candidacy & Sequencing: Identify when to introduce targeted therapies alongside conventional treatments, particularly for patients with refractory disease activity, unacceptable corticosteroid burden, or a need for rapid symptom control.
  • Safety Protocols & Practical Barriers: Implement essential pre-treatment requirements—including meningococcal vaccination, REMS protocols, and infection plans—while navigating infusion burdens, family routines, and insurance coverage

Prefer to read? See our Key Clinical Summary Here.

Target Audience

This program is designed for healthcare professionals involved in the diagnosis, treatment, and longitudinal management of pediatric patients with pediatric myasthenia gravis (PMG). Relevant clinicians include pediatric and general neurologists, neuromuscular specialists, pediatricians, and advanced practice providers, including nurse practitioners and physician assistants.

Faculty

Dr. Abigail N. Schwaede, MD, is an Attending Physician in Neurology at Ann & Robert H. Lurie Children’s Hospital of Chicago and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine. She specializes in pediatric neuromuscular disorders, with expertise in myasthenia gravis and other immune-mediated diseases, as well as Duchenne muscular dystrophy and spinal muscular atrophy. Her research focuses on electrodiagnostic tools and outcome measures in pediatric muscle diseases.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Abigail Schwaede has the following relevant financial relationships: Consultant, Advisor, Speaker: Biogen & Johnson and Johnson.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-367-H01-P

Type of Activity: Knowledge

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until October 15th 2027. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This continuing education activity is active starting October 22nd 2026, and will expire on October 15th 2027.

Estimated time to complete this activity: 15 Minutes

Learning objectives

By the end of this educational program HCP's should be better able to:

  1. Recognize and accurately diagnose JMG through timely evaluation of pediatric patients with suspected neuromuscular junction disorders:

Differentiate JMG from congenital myasthenic syndromes, transient myasthenia, and other pediatric neuromuscular conditions with overlapping clinical presentations. Interpret serologic, electrophysiologic, and clinical findings to support diagnosis in atypical or seronegative presentations. Implement appropriate referral and diagnostic pathways to reduce delays in diagnosis and treatment initiation.

  1. Individualize treatment planning and longitudinal management strategies for pediatric patients with JMG across the disease continuum:

Apply patient-specific factors, including age at onset, disease phenotype, symptom burden, and treatment response, to guide management decisions. Monitor disease progression, treatment effectiveness, and evolving care needs to support timely treatment optimization and shared decision-making. Integrate transition planning and multidisciplinary care approaches to support continuity of management from pediatric to adult services.

  1. Incorporate emerging targeted therapies into evidence-informed treatment planning for patients with JMG:

Evaluate the mechanisms of action, clinical evidence, and potential role of emerging targeted therapies within the evolving JMG treatment landscape. Identify patients who may be appropriate candidates for targeted therapeutic approaches based on disease characteristics and treatment goals. Apply emerging evidence to support individualized treatment selection, sequencing, and long-term management decisions in clinical practice.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

We're gonna talk about applying emerging therapeutics in pediatric imaging. We'll start with the polling question number 5. Which statement about targeted therapies for Myasthenia gravis in children is correct in the United States as of 2026? No targeted therapy is FDA approved for any patient under 18. B, complement inhibitors and FCRN blockers are equally effective in musk positive disease. C, at least one complement inhibitor and one FCN blocker carry US pediatric labeling. D, targeted therapies have replaced corticosteroids as first line treatment in pediatric MG or E, pediatric approvals were based on randomized controlled trials conducted in children. So, the answer here is C. There are 2 treatments that are approved in pediatric patients with MG. One is a complement inhibitor and another is an FCRM blocker. And again, we'll go over those in more detail later in this talk. So why target at all? The problem with broad immunosuppression in a child is many. One, they're slow to work, and they often have many side effects. We know that a growing child who's on immunosuppression can have detrimental effects to growth, so delayed growth velocity, more bone fragility, as well as metabolic and psychological side effects. And many patients with pediatric MG remain refractory to many medications. So what does targeted agents offer? Some targeted agents can allow for more rapid symptom management. They can allow for steroid sparing potential. However, a lot of what we use in pediatrics is extrapolated from adult data, and we don't have as much long-term safety data as well as randomized controlled trials to support evidence in children. So, a lot of what we do in pediatric MG is extrapolated from adult data as well as adult uh real-world data. So the mechanism at the junction. Here I'll point to the finger on the left. We have the nerve terminal where the vesicles with acetylcholine are released into the synaptic cleft. Then we have the muscle membrane right here, where we have first clustering of the acetylcholine receptors, as well as supporting proteins such as musk, which helps with clustering of the acetylcholine receptors. And there's also complement mediated attack that happens in uh autoimmune myasthenia that affects, again, the neuromuscular junction or specifically the muscle membrane. So here we have three different mechanisms that we can target. We have complement inhibition, FCRN blockade, as well as B cell depletion. So in terms of complement inhibition, this is allowing for blocking of the complement activation or the membrane attack complex in that causes damage to the postsynaptic muscle membrane. FCRN blockade is allowing for degradation of these IgG antibodies that are implicated in acetylcholine receptor positive MG rather than having them recycled by the normal pathway of the FCRN receptor. And then B cell depletion, again, is getting at the B cell level, either CD20 or CD19 activity, um, allowing for decrease in production of antibodies, and this is a particularly um relevant in MUS positive antibody disease. So what is approved in children? As I alluded to earlier, there are two medications that are approved in children. One is called eculizumab, and that's a complement inhibitor. And then the other nipocalinab, which is an FCRN blocker. Uh, if you go over to the age range, eculizumab is approved for children 6 and older, as well as adults, and then nibucalumab is approved for children 12 and up, as well as adults. Um, and these were approved, uh, both in February 2025 and April 2025. Uh, there are ongoing trials for another FCRM blocker called FRTigomod and likely to be, be approved in the near future. Um, but again, those studies in children are still ongoing and it is approved in adults with MG. And then there's various other medications you can see listed down here that have various modes of administration, but also working um mainly on the FCRN receptor. So starting with complement inhibition, again, uh, the medication that we have approved in children 6 and up is called eculizumab, and this typically is uh helpful in patients that are acetylcholine receptor positive, um, and typically doesn't help as much with MUSK-positive disease. There's a lot of things you have to do before starting eculizumab as it is targeting the complement system. And the main thing to think about is there's a vaccine requirement, um, that again, you would have to discuss with your patient before initiating treatment. Um, another thing to think about is that this is an infusion and so it does require either in home or in office or in hospital infusions and obviously this can Um, create a, a big burden for the family and the patient. And then given, um, the inhibition of the complement system and the risk of infections due to this immunosuppression, you wanna counsel them on adequate follow-up and making sure that they let you know of any illnesses that might come up. FCRM blockade, again, the medication that is approved in patients 12 and up is called nipecalimab. It is approved for acetylcholine receptor positive and musk-positive patients, although I, I will note that in the pivotal trial for children, um, they did not recruit any musk-positive patients as that's a very rare antibody. Um, and often we're using a lot of the data as well as real-world data, um, from adult population. And what does the FCRN receptor do in um not in uh the FCRN receptor uh naturally helps to recycle IgG antibodies. So what uh nibocalimab is doing is it's blocking that receptor and shut shuffling or shuttling IgG antibodies towards degradation in the lysosome rather than um allowing them to be recycled into the bloodstream. Um, unlike, uh, eculizumab or the complement inhibitor, you do not have a specific vaccine requirement, um, although we always recommend routine vaccinations in a patient with myasthenia. Um, it is administered IV, um, and it is an IV medication that's typically given every other week. Um, so obviously, this can create, uh, a big burden on the family, and we typically recommend trying to have home infusions if that's something the family wants. And then Some of the long-term side effects of um sending IgG antibodies, both pathogenic as well as um non-pathogenic antibodies to lysosomal degradation are really unknown, um, especially in a growing child with a developing immune system. So that's something to think about and we'll need real-world, more real-world data to better understand this. So how good is the pediatric evidence? Like I said, uh, the clinical trials are very small in numbers, and they're mainly extrapolated from adult data. Um, in terms of nipocalimab or the FCRM blocker, there was really only, there were only 7 patients that were enrolled in that study, and then equilizumab. um, had a little bit more, 11 patients. And then you can see the other medications listed here as well as um even thymectomy, um, which do have larger numbers, but the only two treatments that are available in the US currently for children are nipocalumab and eculizumab. So we don't have randomized data, we don't have long-term data as well as, uh, we don't have head to head comparisons, um, to understand really what the best treatment is for a specific child. So does antibody status change the plan? So we have a 16 year old girl with generalized pediatric MG. She's musk antibody positive. She has bulbar predominant symptoms, and she does not respond to pyridostigmine or Mestinon. And she still has symptoms on corticosteroids. So, we could think about, given the MUS positivity, we really wouldn't um favor treating with ecolizumab or complement inhibition, but we could think about an FCRM blocker such as nipocalimab, um, or thinking about a B cell-depleting agent. So, looking at the answers, which targeted options are mechanistically rational for her? A, a complement inhibitor, B, an FCRM blocker, C, a B cell depletion, D, both B and C or E, none. Must disease excludes targeted therapy. So I think this one's a little hard, um, you know, I think you could certainly go with both B and C, um, especially because they're